You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Different initiatives across Europe to enhance losartan utilization post generics: impact and implications
|
|---|---|
| Published in |
Frontiers in Pharmacology, October 2014
|
| DOI | 10.3389/fphar.2014.00219 |
| Pubmed ID | |
| Authors |
James C. Moon, Brian Godman, Max Petzold, Samantha Alvarez-Madrazo, Kathleen Bennett, Iain Bishop, Anna Bucsics, Ulrik Hesse, Andrew Martin, Steven Simoens, Corinne Zara, Rickard E. Malmström |
| Abstract |
There is an urgent need for health authorities across Europe to fully realize potential savings from increased use of generics to sustain their healthcare systems. A variety of strategies were used across Europe following the availability of generic losartan, the first angiotensin receptor blocker (ARB) to be approved and marketed, to enhance its prescribing vs. single-sourced drugs in the class. Demand-side strategies ranged from 100% co-payment for single-sourced ARBs in Denmark to no specific measures. We hypothesized this heterogeneity of approaches would provide opportunities to explore prescribing in a class following patent expiry. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Switzerland | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 61 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Austria | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 59 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 13 | 21% |
| Researcher | 9 | 15% |
| Student > Ph. D. Student | 5 | 8% |
| Professor | 5 | 8% |
| Student > Doctoral Student | 4 | 7% |
| Other | 12 | 20% |
| Unknown | 13 | 21% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 18 | 30% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 15% |
| Social Sciences | 9 | 15% |
| Economics, Econometrics and Finance | 4 | 7% |
| Agricultural and Biological Sciences | 3 | 5% |
| Other | 4 | 7% |
| Unknown | 14 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 08 October 2014.
All research outputs
#20,238,443
of 22,765,347 outputs
Outputs from Frontiers in Pharmacology
#9,993
of 16,009 outputs
Outputs of similar age
#212,925
of 254,867 outputs
Outputs of similar age from Frontiers in Pharmacology
#37
of 50 outputs
Altmetric has tracked 22,765,347 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 16,009 research outputs from this source. They receive a mean Attention Score of 4.9. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 254,867 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.